Supplemental material
Open access
202
Views
0
CrossRef citations to date
0
Altmetric
Real-World Evidence
Real-world clinical outcomes and healthcare costs in patients with Crohn’s disease treated with vedolizumab versus ustekinumab in the United States
Michael Chioreana IBD Center, Gastroenterology, Swedish Medical Center, Seattle, WA, USA
, Jeanne Jiangb HEOR/Value & Evidence Generation, Medical Affairs, Quantitative Clinical Pharmacology, IGI & Neuro and Vaccine, Takeda Development Center Americas, Inc, Lexington, MA, USACorrespondence[email protected]
, Ninfa Candelab HEOR/Value & Evidence Generation, Medical Affairs, Quantitative Clinical Pharmacology, IGI & Neuro and Vaccine, Takeda Development Center Americas, Inc, Lexington, MA, USA
, Grace Chenb HEOR/Value & Evidence Generation, Medical Affairs, Quantitative Clinical Pharmacology, IGI & Neuro and Vaccine, Takeda Development Center Americas, Inc, Lexington, MA, USA
, Hela Romdhanic HEOR, Epidemiology & Market Access, Analysis Group, Inc, Montreal, Canada
, Dominick Latremouille-Viauc HEOR, Epidemiology & Market Access, Analysis Group, Inc, Montreal, Canada
, Sherry Shic HEOR, Epidemiology & Market Access, Analysis Group, Inc, Montreal, Canada
, Rebecca Bungayc HEOR, Epidemiology & Market Access, Analysis Group, Inc, Montreal, Canada
, Annie Guerinc HEOR, Epidemiology & Market Access, Analysis Group, Inc, Montreal, Canada
& Tao Fanb HEOR/Value & Evidence Generation, Medical Affairs, Quantitative Clinical Pharmacology, IGI & Neuro and Vaccine, Takeda Development Center Americas, Inc, Lexington, MA, USA
show all
Pages 877-885
|
Received 13 Jul 2023, Accepted 29 Feb 2024, Published online: 08 Apr 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.